Japanese
Home
About us
Business areas
Contact us
2025.4.11
Termination of License Agreement between TMRC and Syros Pharmaceuticals .
2024.11.13
Syros Pharmaceuticals Inc., announced Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression.
2024.08.14
Syros Pharmaceuticals Inc., has announced that it will no longer be enrolling new patients in its clinical trial for AML.
more info
